Baidu
map

Nat Biotechnol:利用干细胞技术大量制造T细胞

2013-08-19 佚名 生物无忧

在一项新的研究中,来自美国斯隆-凯特琳癌症纪念中心的研究人员利用干细胞技术开发出一种大量制造T细胞的方法;首先收集从体内分离出的T细胞,将它们重编程为诱导性多能干细胞,导入一种基因标记,接着再让这些干细胞变回能够靶向恶性肿瘤细胞的T细胞。相关研究结果于2013年8月11日在线发表在Nature Biotechnology期刊上,论文标题为“Generation of 

在一项新的研究中,来自美国斯隆-凯特琳癌症纪念中心的研究人员利用干细胞技术开发出一种大量制造T细胞的方法;首先收集从体内分离出的T细胞,将它们重编程为诱导性多能干细胞,导入一种基因标记,接着再让这些干细胞变回能够靶向恶性肿瘤细胞的T细胞。相关研究结果于2013年8月11日在线发表在Nature Biotechnology期刊上,论文标题为“Generation of tumortargeted human T lymphocytes from induced pluripotent stem cells for cancer therapy”。【原文下载

这项新的研究是基于去年三月一个研究团队开展的临床试验:它证实经过基因修饰的T细胞能够被用来靶向和摧毁因淋巴母细胞性白血病(lymphoblastic leukemia)而产生的肿瘤。尽管取得了成功,但是这仍很难应用于治疗。在当前这项新的研究中,研究人员开发出一种允许大规模制造重编程T细胞(reprogrammed T cell)的技术,因而使得这种疗法更易于应用。

为了大规模地制造T细胞,研究人员首先从一只供体小鼠体内提取出T细胞。这些T细胞随后经过基因修饰而被重编程为诱导性多能干细胞。接下来,他们将来自一种失活的逆转录病毒的基因信息转移到这些干细胞中。最后一步就是将这些干细胞重编程回T细胞。因为这些新产生的T细胞含有新的基因信息,所以它们能够攻击癌细胞。一旦制造出,这些T细胞随后天然地自我增殖,构建出高达1000个它们的自我拷贝。这些T细胞随后被注射回原始的供体小鼠体内,在那里,它们开始摧毁肿瘤细胞。

研究人员注意到就技术角度而言,这些重编程T细胞并不是真正的T细胞,它们实际上是一种非常类似于T细胞的新类型细胞,而且还具有其他的能力。他们补充到,他们的技术可以构建人们不同类型的T细胞模拟物,从而允许靶向不同类型的癌细胞。

原始出处:

Maria Themeli,Christopher C Kloss,Giovanni Ciriello, Victor D Fedorov,Fabiana Perna, Mithat Gonen & Michel Sadelain.Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy.Nature Biotechnology (2013) doi:10.1038/nbt.2678. 【原文下载

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1652081, encodeId=5a111652081c9, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Sat Oct 05 10:54:00 CST 2013, time=2013-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916974, encodeId=c37f19169e4e2, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Oct 17 22:54:00 CST 2013, time=2013-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927598, encodeId=78e9192e59890, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Tue Jun 10 09:54:00 CST 2014, time=2014-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079662, encodeId=0e8220e9662a6, content=<a href='/topic/show?id=a87448e7286' target=_blank style='color:#2F92EE;'>#干细胞技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48772, encryptionId=a87448e7286, topicName=干细胞技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=jiangjun073, createdTime=Fri Feb 07 16:54:00 CST 2014, time=2014-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879632, encodeId=248818e9632f8, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon May 26 12:54:00 CST 2014, time=2014-05-26, status=1, ipAttribution=)]
    2013-10-05 shock_melon
  2. [GetPortalCommentsPageByObjectIdResponse(id=1652081, encodeId=5a111652081c9, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Sat Oct 05 10:54:00 CST 2013, time=2013-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916974, encodeId=c37f19169e4e2, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Oct 17 22:54:00 CST 2013, time=2013-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927598, encodeId=78e9192e59890, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Tue Jun 10 09:54:00 CST 2014, time=2014-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079662, encodeId=0e8220e9662a6, content=<a href='/topic/show?id=a87448e7286' target=_blank style='color:#2F92EE;'>#干细胞技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48772, encryptionId=a87448e7286, topicName=干细胞技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=jiangjun073, createdTime=Fri Feb 07 16:54:00 CST 2014, time=2014-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879632, encodeId=248818e9632f8, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon May 26 12:54:00 CST 2014, time=2014-05-26, status=1, ipAttribution=)]
    2013-10-17 sunylz
  3. [GetPortalCommentsPageByObjectIdResponse(id=1652081, encodeId=5a111652081c9, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Sat Oct 05 10:54:00 CST 2013, time=2013-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916974, encodeId=c37f19169e4e2, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Oct 17 22:54:00 CST 2013, time=2013-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927598, encodeId=78e9192e59890, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Tue Jun 10 09:54:00 CST 2014, time=2014-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079662, encodeId=0e8220e9662a6, content=<a href='/topic/show?id=a87448e7286' target=_blank style='color:#2F92EE;'>#干细胞技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48772, encryptionId=a87448e7286, topicName=干细胞技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=jiangjun073, createdTime=Fri Feb 07 16:54:00 CST 2014, time=2014-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879632, encodeId=248818e9632f8, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon May 26 12:54:00 CST 2014, time=2014-05-26, status=1, ipAttribution=)]
    2014-06-10 cathymary
  4. [GetPortalCommentsPageByObjectIdResponse(id=1652081, encodeId=5a111652081c9, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Sat Oct 05 10:54:00 CST 2013, time=2013-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916974, encodeId=c37f19169e4e2, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Oct 17 22:54:00 CST 2013, time=2013-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927598, encodeId=78e9192e59890, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Tue Jun 10 09:54:00 CST 2014, time=2014-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079662, encodeId=0e8220e9662a6, content=<a href='/topic/show?id=a87448e7286' target=_blank style='color:#2F92EE;'>#干细胞技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48772, encryptionId=a87448e7286, topicName=干细胞技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=jiangjun073, createdTime=Fri Feb 07 16:54:00 CST 2014, time=2014-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879632, encodeId=248818e9632f8, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon May 26 12:54:00 CST 2014, time=2014-05-26, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1652081, encodeId=5a111652081c9, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Sat Oct 05 10:54:00 CST 2013, time=2013-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916974, encodeId=c37f19169e4e2, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Oct 17 22:54:00 CST 2013, time=2013-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927598, encodeId=78e9192e59890, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Tue Jun 10 09:54:00 CST 2014, time=2014-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079662, encodeId=0e8220e9662a6, content=<a href='/topic/show?id=a87448e7286' target=_blank style='color:#2F92EE;'>#干细胞技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48772, encryptionId=a87448e7286, topicName=干细胞技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=jiangjun073, createdTime=Fri Feb 07 16:54:00 CST 2014, time=2014-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879632, encodeId=248818e9632f8, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon May 26 12:54:00 CST 2014, time=2014-05-26, status=1, ipAttribution=)]
    2014-05-26 liye789132251

相关资讯

Cancer Cell:抗癌“黑马”白细胞介素-11

澳大利亚的研究人员确定了一个称之为白细胞介素-11( interleukin-11 )的分子,是抗癌治疗的一个潜在新靶点。 直到现在,人们都低估了 interleukin-11 在癌症形成中的重要性,近期研究人员确定了这一分子是癌症形成中的一匹“黑马”。他们的研究发现表明,阻断 interleukin-11 信号最终可能成为治疗世界上最常见的两种癌症:肠癌和胃癌的一种新方法。

Nature:发现胃肠道保护生物机制 彻底变革癌症疗法

治疗癌瘤就像用消防栓给室内植物浇水,浇太多会杀死植物,而太多化疗、放疗也会在杀死肿瘤之前先杀死病人。然而,如果病人的胃肠道能保持健康、正常工作的话,生存的机会就会大大增加。 日前,美国密歇根大学科学家发现了一种能保护动物胃肠道的生物机制,他们给小鼠注射了一些分子后再让它们接受致死剂量的化学疗法,发现小鼠的生存率达到了50%-75%。研究人员指出,这一发现有可能彻底变革目前的癌症疗法。相关论文

Nature:里程碑!科学家找到致癌因素“标签”

近日,科学家们发现了隐藏在癌症背后的21个主要的基因突变,这是癌症研究的一个重要里程碑。30种最常见癌症中的97%,都是由这些遗传代码的变化引起的。找出引发这些突变的因素,可以为癌症的治疗提供新的手段。【原文下载】 我们已经知道,吸烟是人们所熟知的致癌因素之一,但是目前有一半以上的致癌因素仍然是未知的。英国癌症研究中心表示,找出致癌因素,是一个既有趣又重要的研究。 当人体的

基因破译引发癌症疗法革命

上个月,凯里和她的医生讨论她肺癌的治疗情况。凯里在2010年被诊断患肺癌后曾被认为只能存活三个月。在被诊断患有肺癌六周后,凯里(Kellie Carey)的医生终于不再回避有关她还能活多久的问题。凯里回忆起当时的情景。2010年5月一个阳光明媚的早晨,这位医生在他的办公室告诉她,也许三个月。然而她现在依然活着。这也证明长期以来科学界抗击肺癌的努力在这10年里取得了长足的进步。检查发现,凯里的肺癌属

Cancer Res:科研人员研制出治癌新药物

澳大利亚科研人员在新一期《癌症研究》杂志上报告说,他们研制出一种能有效杀死癌细胞并且副作用很小的新药,这为治疗癌症带来了新希望。【原文下载】 澳大利亚新南威尔士大学等机构研究人员报告说,这种新药代号为TR100,动物实验显示它可以摧毁两种类型的癌细胞——儿童神经母细胞瘤和黑素瘤。这种新药能迅速锁定癌细胞,并将其内部结构摧毁,同时不会产生较大的毒性副作用。 研究人员正计划用这种新药进行人体临床试

Cell Reports:卵巢癌不良预后的潜在模块化特征

来自中科院上海生命科学研究院计算生物学研究所的研究人员,开发出了一种无偏倚适应成簇(adaptive clustering)方法,综合分析了卵巢癌的基因组、表观基因组和转录组的全景图,由此揭示出了卵巢癌不良预后的潜在模块化特征。这一研究成果发表在8月8日的Cell Reports杂志上。【原文下载】 领导这一研究的是中科院上海生命科学研究院计算生物学研究所所长韩敬东(Ji

Baidu
map
Baidu
map
Baidu
map